Literature DB >> 11937016

The role of C-reactive protein as a prognostic indicator in advanced cancer.

Fade Aziz Mahmoud1, Nilo I Rivera.   

Abstract

C-reactive protein (CRP) is a nonspecific but sensitive marker of inflammation. Interleukin-6 (IL-6), IL-1, and tumor necrosis factor alpha induce the synthesis of CRP in hepatocytes. Increased CRP level is considered to be an important risk factor for atherosclerosis, myocardial infarction, peripheral vascular disease, and ischemic stroke. It is positively correlated with weight loss, anorexia-cachexia syndrome, extent of disease, and recurrence in advanced cancer. Its role as a predictor of survival has been shown in multiple myeloma, melanoma, lymphoma, ovarian, renal, pancreatic, and gastrointestinal tumors. Measurement of CRP is simple, cheap, and routine and provides valuable information in palliative care.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11937016     DOI: 10.1007/s11912-002-0023-1

Source DB:  PubMed          Journal:  Curr Oncol Rep        ISSN: 1523-3790            Impact factor:   5.075


  57 in total

Review 1.  C-reactive protein, inflammation, and coronary risk.

Authors:  D A Morrow; P M Ridker
Journal:  Med Clin North Am       Date:  2000-01       Impact factor: 5.456

Review 2.  Histamine: an early messenger in inflammatory and immune reactions.

Authors:  A Falus; K Merétey
Journal:  Immunol Today       Date:  1992-05

3.  Effect of ibuprofen on the acute-phase response and protein metabolism in patients with cancer and weight loss.

Authors:  T Preston; K C Fearon; D C McMillan; F P Winstanley; C Slater; A Shenkin; D C Carter
Journal:  Br J Surg       Date:  1995-02       Impact factor: 6.939

4.  Suppression of carcass weight loss in cachexia in rats bearing Leydig cell tumor by the novel compound NO-1886, a lipoprotein lipase activator.

Authors:  M Ohara; K Tsutsumi; N Ohsawa
Journal:  Metabolism       Date:  1998-01       Impact factor: 8.694

5.  Relationship between serum levels of interleukin 6, various disease parameters and malnutrition in patients with esophageal squamous cell carcinoma.

Authors:  M Oka; K Yamamoto; M Takahashi; M Hakozaki; T Abe; N Iizuka; S Hazama; K Hirazawa; H Hayashi; A Tangoku; K Hirose; T Ishihara; T Suzuki
Journal:  Cancer Res       Date:  1996-06-15       Impact factor: 12.701

6.  Relation between tumor size, quality of life, and survival in patients with colorectal liver metastases.

Authors:  S Earlam; C Glover; C Fordy; D Burke; T G Allen-Mersh
Journal:  J Clin Oncol       Date:  1996-01       Impact factor: 44.544

7.  Immunoreactive interleukin-6 and acute phase proteins as prognostic factors in multiple myeloma. Finnish Leukemia Group.

Authors:  T T Pelliniemi; K Irjala; K Mattila; K Pulkki; A Rajamäki; A Tienhaara; M Laakso; R Lahtinen
Journal:  Blood       Date:  1995-02-01       Impact factor: 22.113

8.  Ranitidine reduces postoperative interleukin-6 induced C-reactive protein synthesis.

Authors:  L A Rasmussen; H J Nielsen; S Sørensen; C Sørensen; R Rasmussen; S Sørensen; F Moesgaard; J Larsen
Journal:  J Am Coll Surg       Date:  1995-08       Impact factor: 6.113

9.  Evaluation of soluble IL-6 receptor concentration in serum and epithelial lining fluid from patients with interstitial lung diseases.

Authors:  A Yokoyama; N Kohno; Y Hirasawa; K Kondo; M Abe; Y Inoue; S Fujioka; S Fujino; S Ishida; K Hiwada
Journal:  Clin Exp Immunol       Date:  1995-05       Impact factor: 4.330

10.  A prospective randomized study of megestrol acetate and ibuprofen in gastrointestinal cancer patients with weight loss.

Authors:  D C McMillan; S J Wigmore; K C Fearon; P O'Gorman; C E Wright; C S McArdle
Journal:  Br J Cancer       Date:  1999-02       Impact factor: 7.640

View more
  110 in total

1.  Modified glasgow prognostic score as a prognostic factor in gastriccancer patients: a systematic review and meta-analysis.

Authors:  Xinwu Zhang; Xi Chen; Tao Wu; Yan Zhang; Kun Yan; Xiaoli Sun
Journal:  Int J Clin Exp Med       Date:  2015-09-15

Review 2.  Melanoma inhibition by cyclooxygenase inhibitors: role of interleukin-6 suppression, a putative mechanism of action, and clinical implications.

Authors:  R E Kast
Journal:  Med Oncol       Date:  2007       Impact factor: 3.064

3.  The prognostic role of inflammation and hormones in patients with metastatic cancer with cachexia.

Authors:  Cemil Bilir; Huseyin Engin; Murat Can; Yasemin Bakkal Temi; Derya Demirtas
Journal:  Med Oncol       Date:  2015-02-01       Impact factor: 3.064

4.  Understanding tumor anabolism and patient catabolism in cancer-associated cachexia.

Authors:  Alejandro Schcolnik-Cabrera; Alma Chávez-Blanco; Guadalupe Domínguez-Gómez; Alfonso Dueñas-González
Journal:  Am J Cancer Res       Date:  2017-05-01       Impact factor: 6.166

5.  A prospective follow-up study of the relationship between C-reactive protein and human cancer risk in the Chinese Kailuan Female Cohort.

Authors:  Gang Wang; Ni Li; Sheng Chang; Bryan A Bassig; Lanwei Guo; Jiansong Ren; Kai Su; Fang Li; Shuohua Chen; Shouling Wu; Yuhuan Zou; Min Dai; Tongzhang Zheng; Jie He
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2014-12-09       Impact factor: 4.254

6.  Flexible modeling improves assessment of prognostic value of C-reactive protein in advanced non-small cell lung cancer.

Authors:  B Gagnon; M Abrahamowicz; Y Xiao; M-E Beauchamp; N MacDonald; G Kasymjanova; H Kreisman; D Small
Journal:  Br J Cancer       Date:  2010-03-16       Impact factor: 7.640

7.  A phase I/II study of siltuximab (CNTO 328), an anti-interleukin-6 monoclonal antibody, in metastatic renal cell cancer.

Authors:  J-F Rossi; S Négrier; N D James; I Kocak; R Hawkins; H Davis; U Prabhakar; X Qin; P Mulders; B Berns
Journal:  Br J Cancer       Date:  2010-08-31       Impact factor: 7.640

8.  Association of C-reactive protein levels and long-term survival after neoadjuvant therapy and esophagectomy for esophageal cancer.

Authors:  Urs Zingg; Jens Forberger; Branimir Rajcic; Christopher Langton; Glyn G Jamieson
Journal:  J Gastrointest Surg       Date:  2009-11-25       Impact factor: 3.452

9.  A list of candidate cancer biomarkers for targeted proteomics.

Authors:  Malu Polanski; N Leigh Anderson
Journal:  Biomark Insights       Date:  2007-02-07

Review 10.  CRP identifies homeostatic immune oscillations in cancer patients: a potential treatment targeting tool?

Authors:  Brendon J Coventry; Martin L Ashdown; Michael A Quinn; Svetomir N Markovic; Steven L Yatomi-Clarke; Andrew P Robinson
Journal:  J Transl Med       Date:  2009-11-30       Impact factor: 5.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.